The company have substantially boosted its development of the novel therapy for cardiac amyloidosis, utilizing the compound. Initial clinical results suggests potential benefits for those diagnosed from this severe https://bridgebio481074.fitnell.com/83260386/bridgebio-improves-amyloidosis-treatment-through-the-therapy